I-MOVE Multi-Centre Case Control Study 2010-11: Overall and Stratified Estimates of Influenza Vaccine Effectiveness in Europe
I-MOVE Multi-Centre Case Control Study 2010-11: Overall and Stratified Estimates of Influenza Vaccine Effectiveness in Europe
复制标题
DOI：
10.1371/journal.pone.0027622
复制
发表时间：
2011-11-15
期刊：
影响因子：
3.7
通讯作者：
Moren, Alain
中科院分区：
文献类型：
--
作者：
Kissling, Esther;Valenciano, Marta;Moren, Alain
背景资料：在《我动》第三季中（Influenza Monitoring Vaccine Effectiveness in Europe），我们在8个欧盟（EU）成员国开展了一项基于哨点医生监测网络的多中心病例对照研究，以评估2010/11年流感疫苗对实验室确认为流感的医学治疗流感样疾病（ILI）的有效性（VE）。使用系统采样，从业者在症状发作的七天内擦拭ILI/ARI患者。我们比较了符合欧盟ILI病例定义的流感阳性与流感实验室阴性患者。有效疫苗接种对应。从接种疫苗到出现症状间隔14天。我们使用多重插补和链式方程来估计缺失值。使用逻辑回归，研究作为固定效应，我们计算了流感VE调整潜在的混杂因素。我们估计流感VE整体，流感类型，年龄组和目标群体之间的vaccination.Results：我们包括2019例和2391对照分析。调整后的VE总体为52%（95% CI 30-67）（N = 4410），甲型（H1N1）为55%（95% CI 29-72），乙型（B）为50%（95% CI 14-71）。在0-14岁、15-59岁和≥ 60岁人群中，针对所有流感亚型的校正VE分别为66%（95%CI 15-86）、41%（95%CI-3-66）和60%（95%CI 17-81）。接种目标群体（N = 1004），VE为56%（95% CI 34-71）总体，59%（95% CI 32-75）和63%（95% CI 31-81）抗流感B。结论：结果表明，2010-11年三价流感疫苗对医疗参与的ILI实验室的中度保护作用-全欧洲都被确诊为流感采用该多中心病例对照的大样本量，可以进行调整和分层的流感病毒VE估计。I-MOVE展示了一个网络如何在整个欧洲提供精确的VE摘要测量。
Background: In the third season of I-MOVE (Influenza Monitoring Vaccine Effectiveness in Europe), we undertook a multicentre case-control study based on sentinel practitioner surveillance networks in eight European Union (EU) member states to estimate 2010/11 influenza vaccine effectiveness (VE) against medically-attended influenza-like illness (ILI) laboratory-confirmed as influenza.Methods: Using systematic sampling, practitioners swabbed ILI/ARI patients within seven days of symptom onset. We compared influenza-positive to influenza laboratory-negative patients among those meeting the EU ILI case definition. A valid vaccination corresponded to. 14 days between receiving a dose of vaccine and symptom onset. We used multiple imputation with chained equations to estimate missing values. Using logistic regression with study as fixed effect we calculated influenza VE adjusting for potential confounders. We estimated influenza VE overall, by influenza type, age group and among the target group for vaccination.Results: We included 2019 cases and 2391 controls in the analysis. Adjusted VE was 52% (95% CI 30-67) overall (N = 4410), 55% (95% CI 29-72) against A(H1N1) and 50% (95% CI 14-71) against influenza B. Adjusted VE against all influenza subtypes was 66% (95% CI 15-86), 41% (95% CI -3-66) and 60% (95% CI 17-81) among those aged 0-14, 15-59 and >= 60 respectively. Among target groups for vaccination (N = 1004), VE was 56% (95% CI 34-71) overall, 59% (95% CI 32-75) against A(H1N1) and 63% (95% CI 31-81) against influenza B.Conclusions: Results suggest moderate protection from 2010-11 trivalent influenza vaccines against medically-attended ILI laboratory-confirmed as influenza across Europe. Adjusted and stratified influenza VE estimates are possible with the large sample size of this multi-centre case-control. I-MOVE shows how a network can provide precise summary VE measures across Europe.